DigestRedComo funciona
Red
/
Empresas
Te
No verificado

Teva Pharmaceutical Industries Ltd

Sobre qué escribimos

Anuncios brevesFarmacéuticaFinanzasGestión empresarial/Administración de EmpresasMedicina Salud Bienestar

114 Comunicados de prensa

Ver todos los comunicados de prensa
29/07/2026
Farmacéutica
Gestión empresarial/Administración de Empresas
Teva Delivers Strong Q2 Results and Raises Outlook for All Three Key Innovative Brands, Reflecting Continued Execution of Its Pivot to Growth Strategy
Fuente
Teva Pharmaceutical Industries Ltd
Editor
GLOBENEWSWIRE
1.00
0
09/07/2026
Farmacéutica
Teva and Polpharma Biologics Announce Global Licensing Agreement for a Biosimilar Candidate to Ocrevus® (ocrelizumab) for Multiple Sclerosis
Fuente
Teva Pharmaceutical Industries Ltd
Editor
GLOBENEWSWIRE
1.00
0
07/07/2026
Farmacéutica
Teva to Advance Its Anti-IL-15 Antibody, Designed for Quarterly Dosing, Into Phase 2b Development in Vitiligo, Following Encouraging Phase 1b Results
Fuente
Teva Pharmaceutical Industries Ltd
Editor
GLOBENEWSWIRE
1.00
0
18/06/2026
Farmacéutica
Anuncios breves
Teva Releases Q2 2026 Aide Memoire
Fuente
Teva Pharmaceutical Industries Ltd
Editor
GLOBENEWSWIRE
1.00
0
18/06/2026
Farmacéutica
Teva Submits NDA for Ecopipam, a First-in-Class Investigational Therapy for Pediatric Tourette Syndrome
Fuente
Teva Pharmaceutical Industries Ltd
Editor
GLOBENEWSWIRE
1.00
0
18/06/2026
Farmacéutica
Teva to Host Conference Call to Discuss Second Quarter 2026 Financial Results on July 29, 2026 at 8 a.m. ET
Fuente
Teva Pharmaceutical Industries Ltd
Editor
GLOBENEWSWIRE
1.00
0
10/06/2026
Farmacéutica
Teva Closes Acquisition of Emalex Biosciences, Strengthening Late-Stage Neuroscience Pipeline and Advancing Pivot to Growth Strategy 
Fuente
Teva Pharmaceutical Industries Ltd
Editor
GLOBENEWSWIRE
1.00
0
08/06/2026
Farmacéutica
Medicina Salud Bienestar
Teva’s Data on AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablets Highlight Long-Term Advances in Tardive Dyskinesia Treatment and Care
Fuente
Teva Pharmaceutical Industries Ltd
Editor
GLOBENEWSWIRE
1.00
0
05/06/2026
Farmacéutica
Medicina Salud Bienestar
Teva Presents New Data on AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablets that Show Patient- and Caregiver-Reported Improvements in Huntington's Disease Chorea
Fuente
Teva Pharmaceutical Industries Ltd
Editor
GLOBENEWSWIRE
1.00
0
04/06/2026
Farmacéutica
Medicina Salud Bienestar
Anuncios breves
Teva Expands European biosimilars portfolio with launch of AHZANTIVE® (aflibercept) biosimilar to Eylea®
Fuente
Teva Pharmaceutical Industries Ltd
Editor
GLOBENEWSWIRE
1.00
0

Detalles de contacto

Redes sociales

Seguidores
0
Compatibilidad
0